SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association for Continuing Education
Paul Yamauchi, MD, FAAD
Dermatology Institute & Skin Care Center
Clinical Science Institute
Clinical Assistant Professor of Dermatology
David Geffen School of Medicine at UCLA
Adjunct Associate Professor of Dermatology
John Wayne Cancer Institute
Santa Monica, CA

Course Director and Moderator
Brad Glick, DO, MPH, FAOCD
Glick Skin Institute
Skin and Cancer Associates
Program Director - Dermatology Residency
Larkin Hospital - Palm Springs Campus
Clinical Assistant Professor of Dermatology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

: The Evolving Paradigm in Atopic Dermatitis: Integrating Evolving Treatments to Improve Outcomes
Activity/Course #:
: NCME352
: Free
Release/Start Date:
: Jun 30 2018
Expiration Date:
: Jun 29 2019
: Dermatology
Target Audience:
: Dermatologists and Primary Care Providers
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Atopic dermatitis (AD) is a multifactorial, chronic inflammatory and heterogeneous disorder that affects up to 20% of children and up to 3% of adults. The disease is characterized by intense itching, secondary skin infections, and recurrent eczematous lesions, and poses a significant burden on healthcare resources and patients' quality of life. Although it is a frequent disease, AD is underdiagnosed and undertreated. It is estimated that 1.6 million adults with moderate-to-severe AD in the United States remain uncontrolled.

Fortunately, there are existing, new, and upcoming therapies that can dramatically improve AD. This webcast, featuring an interactive discussion between the moderator and faculty responding to live audience questions, will provide an overview of the clinical presentations, comorbidities, diagnosis, and treatments of AD.

This webcast was recorded live at the Conversations in Dermatology Live Virtual Symposium 2018 and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Describe the immunopathogenesis of atopic dermatitis (AD), particularly the role of the Th2 pathway
  2. Recognize the increasing awareness of non-atopic comorbidities associated with AD
  3. Utilize the severity classification and scoring systems in the care of patients with AD
  4. Review the mechanisms of action of recently approved drugs for the treatment of AD

How to obtain your CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  4. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Creditô. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hours of continuing education which includes .75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Dr. Yamauchi serves as a speaker, consultant, and Investigator for Regeneron and Pfizer, and a speaker for Sanofi-Aventis.

Dr. Glick serves on the speakerís bureau for SunPharma/Ranbaxy, Merz, LEO, Abbvie, Janssen, Celgene, Galderma, Lilly, Novartis Pharmaceuticals Corporation and Ortho Dermatologics. Dr. Glick is also a member of the advisory board for Lilly and TopMD stockholder.

Josh Killbridge, Medical Writer, has no relationship to disclose.

Gregg Sherman, MD, Activity Planning Committee, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Daniela Hiedra, BA, Activity Planning Committee has no relationships to disclose.

Sandy Bihlmeyer, MEd, Activity Planning Committee, has no relationship to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.